Novartis Gets Phase 3-Ready Rare Kidney Disease Drug via $800M Regulus Acquisition

**Novartis Acquires Phase 3-Ready Kidney Disease Drug in $800M Deal**

Novartis has acquired farabursen, a drug developed by Regulus Therapeutics, in an $800 million transaction. Farabursen is positioned as a potential first-in-class treatment for a rare kidney disease that currently has limited therapeutic options. The only FDA-approved therapy for this condition carries significant toxicity risks, highlighting the need for alternative treatments. With this acquisition, Novartis adds farabursen to its portfolio of therapies targeting rare renal disorders.

Farabursen is ready to enter Phase 3 clinical trials and represents a strategic addition to Novartis’s existing lineup of drugs addressing rare kidney diseases. The acquisition underscores Novartis’s focus on expanding its presence in the renal disorder space while addressing unmet medical needs. Regulus Therapeutics developed farabursen with the aim of providing safer and more effective treatment options for patients affected by this challenging condition.

Newsflash | Powered by GeneOnline AI

Source: https://medcitynews.com/2025/04/novartis-regulus-acquisition-rare-kidney-disease-renal-farabursen-nvs-rgls/

Author

Mark Chiang